Exploring Oral Health Equity and Cancer Prevention Among Adults Living With HIV from Diverse Racial, Ethnic, and Sexual and Gender Minority Groups
Led by University of California, San Francisco · Updated on 2026-06-18
144
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What this Trial Is About
Researchers are conducting an exploratory qualitative study among people living with HIV PLWH who belong to diverse racial, ethnic, sexual, and gender minority groups. The study aims to explore various factors affecting oral health equity, including barriers and facilitators to accessing oral health care. It also seeks to understand knowledge and perceptions about human papillomavirus HPV vaccination and oral and oropharyngeal squamous cell carcinoma OSCCOPSCC, and to gather recommendations for improving access to dental care and prevention strategies.
Participants will engage in a single focus group discussion lasting about 1.5 to 2 hours, facilitated to encourage sharing within groups of shared identity. Before this, they will complete a brief quantitative survey electronically or by phone. The focus group discussions will be recorded, transcribed, and analyzed to identify oral health equity factors. There are no drug or device interventions the study gathers qualitative and survey data.
Involvement includes one screening and enrollment phone call followed by one study visit for the focus group and survey. Researchers will measure potential oral health equity factors within up to three days. Participants knowledge, perceptions, and recommendations regarding oral health care and cancer prevention will be collected. The total participation time is limited to these activities, with no long-term follow-up or treatment provided.
CONDITIONS
Brief Title
People Living With HIV, Oral and Oropharyngeal Cancer, and Health Equity
Research Team
W
William Juarez
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
National Institute of Dental and Craniofacial Research (NIDCR)
Collaborating Sponsor
Who Can Participate
Age: 18Years +
All Genders
Eligibility Criteria
You may qualify if you...
Participants must be 18-years old or older.
Participants must be individuals living with HIV.
Ability to speak and understand English.
Identify as one or more racial/ethnic minority groups or sexual and gender minority groups.
All genders and members of all races and ethnic groups are eligible for this study.
You will not qualify if you...
Younger than 18-years old.
Not living with HIV.
Not able to speak and understand English.
Not classified as one or more racial/ethnic minority groups or sexual and gender minority groups.
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 screening and enrollment phone call
Focus Group Visit
Duration - Single visit
Participants complete a short survey and take part in a 1.5 to 2-hour facilitated focus group discussion. The sessions are recorded and later analyzed.
1 visit (in-person or remote)
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Similar Trials
Study of Ultra-High Frequency Intraoral Ultrasound for Oral Squamous Cell Carcinoma Diagnosis and Assessment
Long-term Follow-up Study of Adults with HIV Previously in HIV-NAT Trials
Observing Safety, Treatment Effects, and Quality of Life
Phase 2b Study Comparing Oral VH4524184 with Standard HIV Treatment in Adults Newly Diagnosed with HIV-1
Evaluating Treatment Strategies for Managing Virologic Failure on Tenofovir, Lamivudine, and Dolutegravir TLD in People with HIV in Sub-Saharan Africa
Pilot Study of a Peer-Driven Injection Setting Intervention to Prevent HIV, Hepatitis C, and Overdose Among People Who Inject Drugs in Baltimore
Study of PRV111, PRV211, and PRV131 Nanoengineered Therapies for Oral and Lung Cancers
Evaluating Safety and Effectiveness in Different Treatment Approaches
Phase II Study of Sacituzumab Govitecan and Cetuximab for Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma After First-Line Therapy
Phase 1 Study of VH4011499 Safety, Tolerability, and Pharmacokinetics
with Single and Multiple Doses in Adults Without HIV
Safety and Effectiveness of JL18008 Injections Added to Standard HIV Therapy
in Adults with HIV Who Have Low Immune Response
A Randomized, Double-Blind, Placebo-Controlled Phase III Study
Phase 12 Study to Assess Safety and Effects of Cabotegravir in Newborns Exposed to HIV-1
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Using an anti-racist research framework to design studies of oral human papillomavirus and oropharyngeal cancer in San Francisco: rationale and protocol for the Health Equity and Oral Health in People living with HIV (HEOHP) qualitative study.
Alexandra L Hernandez, Elena O Lingas, William Juarez...